|Bid||16.56 x 1800|
|Ask||16.45 x 3100|
|Day's Range||15.04 - 17.02|
|52 Week Range||4.41 - 67.00|
|Beta (5Y Monthly)||2.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 17, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.98|
Canadian cannabis company Tilray (NASDAQ: TLRY) hasn't reported first quarter 2021 financial results yet, but another earnings report in April had an immediate impact on Tilray stock. Canadian peer Aphria reported its financial update on April 12, and disappointed investors sold off Tilray stock, too, knocking it down 13% on the day. The newly combined company using the Tilray name is being led by former Aphria CEO Irwin Simon.
Jefferies analyst Owen Bennett raised his rating on Tilray's stock from underperform to buy. Bennett believes the combination of Aphria and Tilray is a "perfect match," as it brings together their leading positions in Canada and international markets. With a large global geographic footprint, industry-leading operational scale, and low-cost production facilities, Tilray is poised to compete and win in the rapidly expanding cannabis market.
The Nasdaq Composite (NASDAQINDEX: ^IXIC) has gotten left out of the stock market party recently, as it hasn't been able to match the performance of other market benchmarks that have climbed to new all-time highs. The Nasdaq has a lot of growth stocks, and many of those top names have suffered pullbacks in 2021 after impressive performance last year. Datadog (NASDAQ: DDOG) managed to claw back part of its lost ground on Friday as investors looked at its most recent earnings.